Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept in Very Low Vision Secondary to Wet AMD
NCT02098720Phase 2Unknown
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Dec 2011
- Primary completion
- Mar 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of conbercept in exudative macular degeneration, sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoint: Percentage of patients with best corrected visual acuity (BCVA) >= 19 letters gain at 6 months. Status: unknown.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02098720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098720.